Results 161 to 170 of about 659,249 (217)

Maternal nutrition as a key determinant of placental and developing blood–brain barrier xenobiotic protective functions

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Suboptimal maternal nutrition alters placental and developing blood–brain barrier (BBB) protective function and is associated with increased fetal brain vulnerability. In the placenta, nutritional adversity may reduce the exchange surface area and promote meta‐inflammation, compromising barrier efficiency in a model‐ and context ...
Kristin L. Connor   +4 more
wiley   +1 more source

microRNA‐145‐5p regulates P‐glycoprotein and breast cancer resistance protein in primary human fetal brain endothelial cells

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Drug transporters P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) at the blood–brain barrier (BBB) protect the rapidly developing fetal brain. We investigated the role of microRNA‐145‐5p (miR‐145‐5p) microRNA (miRNA) in regulating these key transporters in primary human fetal brain endothelial cells in vitro. We
Phetcharawan Lye   +5 more
wiley   +1 more source

Characterization of the Lysophosphatidic Acid Receptor 5 Antagonist RLPA‐76 as a Novel Analgesic in Male Rats and Mice

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 6, December 2026.
ABSTRACT Clinically used analgesics such as gabapentinoids and opioids have limited efficacy and adverse effects like abuse liability, and there is a dire need for novel analgesics with improved safety profiles. Since lysophosphatidic acid can induce neuropathic pain in rodents, LPA receptor antagonists have been investigated as potential analgesics ...
Kristen L. Woodhouse   +6 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11143-11177, December 2026.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding   +4 more
wiley   +1 more source

A Cu2S/NiOOH Heterojunction Enables Highly Selective Ammonia‐to‐Nitrite Electrooxidation at Industrially Relevant Current Densities

open access: yesAdvanced Materials, Volume 38, Issue 62, 6 November 2026.
Cu2S/NiOOH heterojunction enables efficient ammonia electrooxidation coupled with hydrogen evolution. Interfacial electronic modulation of Ni sites promotes selective NH3‐to‐NO2− electrooxidation at high current density. In a membrane electrode assembly, Cu2S/NiOOH maintains over 90% Faradaic efficiency of nitrite at 800 mA cm−2, highlighting its ...
Ke Wang   +13 more
wiley   +1 more source

Self‐Amplified Activatable Fluorescent Probe for Early Diagnosis of Acute Kidney Injury and High‐Throughput Screening of Natural Protectants

open access: yesAdvanced Science, Volume 13, Issue 61, 3 November 2026.
The PS‐QRC nanoprobe employs L‐serine as a targeting ligand for kidney injury molecule‐1 (KIM‐1) to achieve accumulation in injured renal tissues. Upon activation by reactive oxygen species (ROS), it undergoes a self‐amplifying cascade to release fluorophores for near‐infrared fluorescence (NIRF) imaging, enabling ultra‐early diagnosis of acute kidney ...
Yahui Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy